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Aims Therapy with an implantable cardioverter defibrillator (ICD) is established for the prevention of sudden cardiac
death (SCD) in high risk patients. We aimed to determine the effectiveness of primary prevention ICD therapy by
analysing registry data from 14 centres in 11 European countries compiled between 2002 and 2014, with emphasis
on outcomes in women who have been underrepresented in all trials.
...................................................................................................................................................................................................
Methods
and results
Retrospective data of 14 local registries of primary prevention ICD implantations between 2002 and 2014 were
compiled in a central database. Predefined primary outcome measures were overall mortality and first appropriate
and first inappropriate shocks. A multivariable model enforcing a common hazard ratio for sex category across the
centres, but allowing for centre-specific baseline hazards and centre specific effects of other covariates, was ad-
justed for age, the presence of ischaemic cardiomyopathy or a CRT-D, and left ventricular ejection fraction <_25%.
Of the 5033 patients, 957 (19%) were women. During a median follow-up of 33 months (IQR 16–55 months) 129
women (13%) and 807 men (20%) died (HR 0.65; 95% CI: [0.53, 0.79], P-value < 0.0001). An appropriate ICD
shock occurred in 66 women (8%) and 514 men (14%; HR 0.61; 95% CI: 0.47–0.79; P= 0.0002).
...................................................................................................................................................................................................
Conclusion Our retrospective analysis of 14 local registries in 11 European countries demonstrates that fewer women than
men undergo ICD implantation for primary prevention. After multivariate adjustment, women have a significantly
lower mortality and receive fewer appropriate ICD shocks.
                                                                                                                                                                                                                   
* Corresponding author. Tel: þ41 61 265 5214; fax: þ41 61 265 4598. E-mail address: Christian.Sticherling@usb.ch
VC The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
Europace (2018) 20, 963–970 CLINICAL RESEARCH
doi:10.1093/europace/eux176 Sudden death and ICDs
D
ow
nloaded from
 https://academ
ic.oup.com
/europace/article-abstract/20/6/963/3897335 by R
oyal Library C
openhagen U
niversity user on 05 M
arch 2019
Keywords Implantable defibrillator • Sudden cardiac death • Primary prevention • Ventricular fibrillation • Cardiac
resynchronization therapy • Women • Sex differences • Heart failure
The implantation of an implantable cardioverter defibrillator (ICD)
has been established as a cornerstone for the prevention of sudden
cardiac death (SCD) in high risk patients since the publication of land-
mark studies more than a decade ago.1,2 Despite its widespread use,
most ICD recipients will never receive an ICD shock.4 This urges
the identification of appropriate diagnostic risk stratifiers that predict
the occurrence of life-threatening ventricular arrhythmias in this
population.3,4
Despite extensive research on numerous recognized non-invasive
ECG-derived markers for increased arrhythmia risk, the only com-
monly employed ‘risk predictor’ remains an impaired left ventricular
ejection fraction (LVEF), a marker that occasionally can be difficult to
quantifiy accurately and also predicts non-arrhythmic death.5
Currently, more than 100 000 ICDs are annually implanted in the
countries of the EU at a cost exceeding 2 billion Euro. Apart from its
high cost, ICD therapy can cause unwanted side effects like inappro-
priate shocks, infection, and lead fractures which lead to additional
morbidity and even mortality.6 There is the competing risk of other
non-cardiac medical conditions—e.g. malignancies or end-stage renal
disease—which may cause the death of an ICD recipient before ever
receiving a life-saving ICD therapy.3,7
Finally, for a variety of reasons primary prevention ICD implant-
ation rates are vastly different between countries and it is unknown
whether this leads to different rates of ICD therapy in the respective
countries.8
By retrospectively combining the data from 14 local institutional
registries in 11 European countries, we aimed to assess the mortality
and the rate of appropriate and inappropriate shocks in a contem-
porary real life European primary prevention ICD population. Since
women are underrepresented in all major trials, we strived to com-
pare outcome data between female and male participants.
Methods
The EU-CERT-ICD project is funded by the European Community’s 7th
Framework Programme FP7/2007-2013 (grant agreement number
602299). The prospective arm will enrol 2500 patients with an indication
for a primary prevention ICD implantation who will also undergo analysis
of numerous candidate ECG markers from 12-lead Holter recordings as
stratifiers for a higher risk of malignant arrhythmias. Our data stem from
an associated work package 02, a retrospective compilation of 14 locally
existing mostly prospective registries of primary prevention ICD implant-
ations between 2002 and 2014.
Data collection
Twenty-three demographic, device- and outcome-related variables were
predefined, the collection of 17 additional variables was encouraged
whenever feasible (see Supplementary material online, Table S1). As out-
comes, all-cause mortality and appropriate ICD shock therapy were man-
datory. Appropriate ICD shock delivery was considered as the best
surrogate parameter for prevented SCD. Local investigators pre-
processed their datasets accordingly and sent them to the coordinating
clinical trial unit of the University Hospital of Basel, Switzerland. Here the
registries were merged into a single SecuTrial database (interActive
Systems, Berlin, Germany). System generated queries were thereafter ad-
dressed until the database was closed on 1 September 2015 and then for-
warded for statistical analysis to the University of Go¨ttingen, Germany.
Statistics
All patients with ischaemic or non-ischaemic cardiomyopathy, a primary
prevention ICD implantation between February 2002 and December
2014 and a LVEF <_35% were analysed. If an exact date for an event was
not available, we used the 15th of the respective month in the analysis (or
the last follow-up date, if this happened to be in the same month earlier
than on the 15th). For two patients, an appropriate shock was observed
on the day of implantation. Their time on study was set to 0.5 days re-
garding that endpoint.
Continuous variables are reported as means and standard deviations,
categorical variables as frequencies. Median follow-up is evaluated as the
median time on study when considering all patients. Cumulative incidences
for the end-points are estimated using Aalen–Johansen estimators, the
pointwise confidence intervals (CIs) are constructed using the
Greenwood-type estimator for the variance and log-minus-log transform-
ation applied to one-cumulative incidence, as described by Beyersmann9
and implemented in R package etm.10 The hazard ratios for gender are eval-
uated using the Fine and Gray subdistributional hazard models accounting
for the competing risks.11,12 The proportionality of hazards was checked by
visual inspection of Schoenfeld residuals. We considered several models. A
multivariable model enforcing a common hazard ratio for gender across
the centres, but allowing for centre-specific baseline hazards and centre-
specific effects of other covariates, was adjusted for age, ischaemic cardio-
myopathy, LVEF <_ 25% and cardiac resynchronization therapy ICD (CRT-
D). These covariates were fully observed in the analysed cohort. (Due to a
lower number of events regarding the first inappropriate shock, effects of
the covariates were not considered centre-specific for this end-point.)
To examine whether the effect of gender on the selected endpoints
differs between patients with CRT-D and those with ICD only, we
included an additional term for gender by CRT-D interactions in the
models. We examined also influences of calendar time of the ICD im-
plantation, since the patients underwent ICD implantation over a large
What’s new?
• Women less often undergo primary preventive ICD implant-
ation than men.
• In our contemporary cohort of 5033 European recipients of a
primary preventive ICD, the mortality of women is significantly
lower (HR 0.65; 95% CI: [0.53, 0.79], P-value < 0.0001).
• Women also receive significantly fewer first appropriate ICD
shocks (HR 0.61; 95% CI: 0.47–0.79; P= 0.0002).
• The incidence of a first inappropriate shock does not differ.
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time span. When examining temporal trends, we limited the maximum
follow-up to 5 years and considered only patients with ICD implantation
in June 2013 at the latest. This was done to guard against effects only gen-
erated by longer follow-ups due to earlier ICD implantation. In addition,
in case of the first inappropriate shock, we analysed only patients
undergoing the implantation in and after 2007, since prior to this year, we
had data only from a single centre. In order to examine how realistic a
common hazard ratio for gender across the centres is, we analysed
centres individually, in which case the centre-specific hazard ratios for
gender (adjusted for age, ischaemic cardiomyopathy, LVEF <_ 25% and
CRT-D) were meta-analysed (on log-scale) using the random effects
model with the Mandel–Paule estimator of the between study variance.
The 95% CI for the pooled hazard ratio was calculated using the modified
Knapp-Hartung approach.13 The between-study heterogeneity was as-
sessed by the Cochran Q v2 test and by the I2 measure (as implemented
in the R package metafor14) All analyses were done using the R software
(R Foundation for Statistical Computing, Vienna, Austria). A P-val-
ue < 0.05 was pre-specified to indicate statistical significance.
Results
Data from 5111 patients from 14 European centres, in 11 countries,
were available. After exclusion of 78 patients with incomplete follow-
up, 5033 patients were analysed for the endpoint of all-cause
mortality.
Nine-hundred-fifty-seven (19%) were female, the mean age at im-
plantation was 64 ± 11 years, 65% suffered from ischaemic cardiomy-
opathy and 43% received a CRT-D (Table 1). Median follow-up was
33 months (IQR 16–55 months).
Overall mortality
During the follow-up, 936 patients died (19%, Figure 1). Seventy-
seven patients (17 women, 60 men) underwent heart transplantation.
The estimated cumulative incidence curves and their 95% CI showed
a significantly lower mortality for women (129 deaths; 13%) than for
men (807 deaths; 20%). The hazard ratio for gender adjusted for age,
the presence of ischaemic cardiomyopathy, LVEF <_25 and the pres-
ence of a CRT-D was 0.65 (95% CI: [0.53, 0.79], P-value < 0.0001).
The overall 2-year mortality rate of 10% and significantly lower in
women (7%) than in men (11%; P= 0.0005, Figure 2). The centre-
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of patients included in the analysis of the all-cause mortality
Females, n5 957 Males, n54076 Total, n5 5033
Age (years) 64 ± 11 64 ± 11 64 ± 11
LVEF <_ 25% 59% 55% 56%
CRT-D 51% 42% 43%
ICM 47% 69% 65%
QRS* (ms) 132 ± 33 (NA: 23%) 131 ± 34 (NA: 30%) 132 ± 34 (NA: 30%)
Creatinine* (mg/dL) 1.1 ± 0.6 (NA: 30%) 1.3 ± 0.8 (NA: 29%) 1.3 ± 0.8 (NA: 30%)
AF* 14% (NA: 34%) 22% (NA: 34%) 20% (NA: 34%)
Diabetes* 16% (NA: 36%) 20% (NA: 30%) 19% (NA: 31%)
Amiodarone* 6% (NA: 35%) 9% (NA: 31%) 9% (NA: 32%)
Beta-blocker* 66% (NA: 24%) 69% (NA: 22%) 68% (NA: 22%)
NYHA class* (NA: 7%) (NA: 7%) (NA: 7%)
I 4% 7% 6%
II 31% 38% 37%
III 53% 45% 46%
IV 4% 4% 4%
The values are depicted as mean ± SD or percentages. In case of not fully observed variables (denoted with *), the number in brackets states the proportion of missing values
(NA).
LVEF, left ventricular ejection fraction; ICM, ischaemic cardiomyopathy; AF, atrial fibrillation; NA, not applicable; NYHA, New York York Assocation; CRT-D, cardiac resynch-
ronization therapy implantable cardioverter defibrillator.
Figure 1 Cumulative incidences of all-cause mortality in the
cohort and individual centres.
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specific hazard ratios for all the other covariates included in the
model are shown in see Supplementary material online, Table S2.
Analysis of individual centres showed no evidence for heterogen-
eity (I2 ¼ 0, heterogeneity test P-value 0.7914) regarding the hazard
ratio for gender and the pooled estimate was 0.68 (females/males,
95% CI: [0.54, 0.86], P-value 0.0045; Figure 3). In this centre-specific
analysis, we considered only centres with at least 10 females, at least
1 death observed (among men and women) and with at least 10
observed death in total.
Examining the effect of sex category on cumulative incidence of
death between ICD- and CRT-D patients yielded an estimated hazard
ratio for gender (females/males) in CRT-D patients of 0.57, 95% CI:
[0.43, 0.75], in patients with only ICDs as 0.76, 95% CI: [0.58, 1.0].
However, the interaction term (and thus the apparent difference be-
tween the hazard ratios) was not statistically significant (P-value 0.1269).
Appropriate implantable cardioverter
defibrillator shock
For the analysis of the time to the first appropriate shock we had data
available in 13 centres (4548 patients), from which 139 patients were
excluded due to insufficient data. Our results did not appear sensitive
to the resulting selection bias (Table 2, full sensitivity analysis not re-
ported). We chose to analyse appropriate ICD shocks as the closest
surrogate parameter for prevented SCD.
The remaining cohort of 4409 patients was followed for a median
of 29 months (IQR: 14–50 months). The median follow-up times
ranged from 20 to 48 months. During follow-up, 566 patients
experienced their first appropriate shock (65 females and 501 males,
Figure 4). The endpoint of first appropriate shock competed with the
endpoints of death and heart transplantation, two events leading to
censoring. In our cohort, 95 females (11%) and 584 males (16%) died
before receiving an appropriate shock and another 13 females (2%)
and 50 males (1%) underwent heart transplantation prior to any ap-
propriate shock.
The estimated cumulative incidence curves and their 95% CI
showed a significantly lower number of first appropriate ICD shocks
for women (Figure 5).
The hazard ratio for a first appropriate shock for female gender ad-
justed for age, the presence of ischaemic cardiomyopathy,
LVEF <_ 25% and the presence of a CRT-D was 0.61 (95% CI:
[0.47,0.80]; P-value 0.0003). See Supplementary material online, Table
S2 lists estimated hazard ratios for all other covariates in the model.
Per centre analysis revealed no evidence for heterogeneity (I2¼ 0,
heterogeneity test P-value 0.8788) and the pooled result (HR fe-
males/males): 0.66, 95% CI: [0.48, 0.91], P-value 0.0179) was not sub-
stantially different from the result obtained previously, assuming a
common gender effect across centres (Figure 6).
Patients with a CRT-D received fewer first appropriate shocks
than those without biventricular pacing.
Adding an interaction term for gender and CRT-D (common for
all centres) to the multivariable model, we did not observe any signifi-
cant difference between the hazard ratios for gender regarding first
appropriate shock in CRT-D and ICD only patients (P-value 0.7578).
The estimated hazard ratios for gender (females/males) were practic-
ally identical both for CRT-D patients and patients with only ICDs
(0.59, 95% CI: [0.40, 0.87] vs. 0.64 95% CI: [0.45, 0.90]).
Figure 2 Cumulative incidences of all-cause mortality by gender
(with 95% CIs).
RHC, n=1008
All-cause mortality
UMCU, n=634
UMG, n=670
UHBS, n=487
UHZ, n=485
KUL, n=323
TUM, n=328
MUL, n=236
Kl, n=206
SUH, n=272
0.57 [0.38 , 0.86]
0.52 [0.30 , 0.90]
0.76 [0.50 , 1.17]
0.79 [0.40 , 1.55]
0.81 [0.41 , 1.59]
0.90 [0.32 , 2.52]
0.40 [0.10 , 1.55]
0.38 [0.11 , 1.27]
0.88 [0.42 , 1.87]
0.94 [0.47 , 1.85]
0.68 [0.54 , 0.86]Pooled hazard ratio
0.1 0.5
Hazard ratio females/males
1.0 5.0 10.0
RE Model, Heterogeneity: I2=0%
Figure 3 Forest plot of estimated centre-specific hazard ratios
for gender regarding overall-mortality together with their 95% CIs
and the pooled hazard ratio with a modified Knapp-Hartung 95%
CI. (Note that not all centres were included in this analysis.).
“Abbreviations of the centers can be found in the supplementary
material”.
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Inappropriate implantable cardioverter
defibrillator shocks
For the analysis of the time to the first inappropriate shock, we had
data available only in three centres (1516 patients), from which we
excluded further 12 patients due to insufficient data.
The remaining cohort of 1504 patients was followed for a median
of 31 months (IQR: 17–53 months). The median follow-up times in
the three individual centres were 23, 27, and 37 months. During the
follow-up 87 patients experienced a first inappropriate shock (6%, 14
females and 73 males, see Supplementary material online, Figure S1).
The endpoint of first inappropriate shock competed with the end-
points of death and heart transplantation, two events censoring the
patients. In our cohort, 29 females and 211 males died and 10 females
and 36 males underwent heart transplantation prior to any inappro-
priate shock.
The estimated cumulative incidence curves and their 95% CI do
not suggest a sex difference regarding the number of first inappropri-
ate ICD shocks (see Supplementary material online, Figure S2)
The hazard ratio for female gender adjusted for age, the presence
of ischaemic cardiomyopathy, LVEF <_ 25% and the presence of a
CRT-D was 0.79 (95% CI: 0.43, 1.42]; P-value 0.47). Hazard ratios for
the other covariates in the model are shown in Table 2.
Temporal trends
We observed a decrease in the cumulative incidence of first appro-
priate shocks in relation to the year of implantation (HR for time of
ICD implantation [years] 0.95, CI 0.90–0.99, P= 0.022).
Among 1168 patients implanted in 2002–07, we observed 216 first
appropriate shocks (18%, 5.1 first appropriate shocks per 100
person-years), among 3048 patients implanted in 2008–13, we
observed 314 first appropriate shocks (10%, 4.2 first appropriate
....................................................................................................................................................................................................................
Table 2 Hazard ratios with 95% CIs from multivariable models fitted for the different end-points under the assump-
tion of common covariate effects across centres and allowing for centre-specific baseline hazards. (Estimates regarding
appropriate shock are obtained after disregarding the centre with underrepresented CRT-D patients.)
End-point Female Age(years) LVEF25% ICM CRT-D
Mortality 0.68 1.04 1.61 1.35 1.13
0.56–0.82 1.03–1.05 1.40–1.85 1.15–1.58 0.98–1.30
First appropriate shock 0.59 1.00 1.49 1.24 0.80
0.45–0.77 0.99–1.01 1.25–1.78 1.01–1.52 0.66–0.96
First inappropriate shock 0.79 0.98 1.24 0.79 0.82
0.44–1.42 0.96–0.99 0.80–1.94 0.48–1.29 0.51–1.32
Note that if 1 is not included in the reported CI, the hazard ratio is significant.
LVEF, left ventricular ejection fraction; CRT-D, cardiac resynchronization therapy implantable cardioverter defibrillator.
Figure 4 Cumulative incidences of first appropriate shocks in
cohort and individual centres.
Figure 5 Cumulative incidences of first appropriate shocks by
gender (with 95% CIs).
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shocks per 100 person-years). Temporal trends were not different
with regard to sex category (P= 0.69), and could not be demon-
strated in the cumulative incidence of first inappropriate shock
(P= 0.46), or overall mortality (P= 0.60).
Discussion
The main result of our European multicentre analysis is that the pri-
mary prevention ICD implantation rate is consistently low in women.
Women exhibit a lower overall mortality and receive fewer appro-
priate ICD shocks than their male counterparts. Yet, their risk of
experiencing inappropriate ICD shock is equal.
Implantation rates
In our large retrospective cohort, women constituted 19% of pa-
tients implanted ranging from 8 to 28% in the individual centres.
Female underrepresentation has been a consistent finding in all
randomized controlled primary prevention ICD trials1,2,15–18 and
subgroup analyses failed to show a significant mortality reduction for
women in all trials. Therefore, the evidence for the efficacy of primary
prevention ICD use is lower in women.
Our data indicate that lower implantation rates in women are con-
sistent across Europe and not a regional finding. A recently published
study from a multicentre cohort of 5539 French ICD recipients with
a primary prevention indication showed that only 15% of recipients
were female and thus corroborates our findings.19
Gender differences in overall-mortality
and appropriate implantable cardi-
overter defibrillator therapy
We could demonstrate that the overall-mortality over a median fol-
low up of 33 months was significantly lower in women than in men.
This finding is based on 14 centres in 11 European countries.
Although the proportion of women with non-ischaemic cardiomyop-
athy was higher, this finding remained significant after adjustment for
confounding co-variates with a HR of 0.65.
This corroborates the results of our recent systematic review and
meta-analysis, in which we found an adjusted HR in women of 0.75
for overall mortality.20
In the MADIT-II study, enrolling only patients post-myocardial in-
farction, the 2 year mortality rate was 15% in the intervention group.1
The SCD-Heft trial enrolled patients with ischaemic and non-ischae-
mic cardiomyopathy and had a 2 year mortality rate of 11–12%.2 Of
note, only 15 and 22%, respectively of the participants were females
and subgroup analysis did not show a mortality benefit for women.
In fact, our data corroborates these findings with an overall 2 year
mortality rate of 10% and a significantly lower mortality in women
(7%) than in men (11%). The unchanged overall mortality as com-
pared to the selected patients enrolled in SCD-HeFT is of interest,
since that means that improvements in drug therapy of heart failure
and changes in revascularization therapy did not show a lower mor-
tality in our unselected cohort (enrolled and followed between 2002
and 2015).
Recent studies from the Netherlands and Germany showed very
similar results with lower mortality in women with primary preven-
tion ICD (HR 0.65) and a trend towards fewer appropriate therapies
in women.21,22 Our study results point into the same direction and in-
dicate that these results are not only a single centre observation but
a general finding in an unselected European primary prevention ICD
population. Data from the primary prevention ICD patients with
ischaemic heart disease enrolled in the Danish ICD registry also
showed a trend towards higher mortality in men.23 In patients with
non-ischaemic cardiomyopathy, however, there was no difference in
mortality.16
In contrast to our results, the French DAI-PP registry only showed
a lower mortality in women receiving a CRT-D (HR 0.68; P= 0.034)
but no significant lower mortality of women in the overall primary
prevention ICD cohort (HR 0.87; P= 0.32).17 This difference to our
findings can in part be explained by the fact that 61% of women in the
French study but only 51% in our study received a CRT-D. Like in
our cohort, the rate of appropriate ICD therapy was significantly
lower in females compared to males (HR 0.61), whereas the rate of
inappropriate therapies did not differ.
The reasons for lower mortality of female primary prevention ICD
patients are not entirely understood. One possible explanation is
that the proportion of patients with non-ischaemic cardiomyopathy
is consistently significantly higher and exceeds mostly 50% in women.
The presence of non-ischaemic cardiomyopathy is associated with a
lower overall mortality when compared to patients with ischaemic
cardiomyopathy.1,15,17,24,25 It can also not be ruled out that there is a
RHC, n=1001
First appropriate shock
UMCU, n=630
UMG, n=670
UHBS, n=487
KUL, n=323
TUM, n=326
KI, n=204
SMU, n=180
SUH, n=154
0.56 [0.33 , 0.95]
0.65 [0.33 , 1.30]
0.47 [0.24 , 0.93]
0.53 [0.21 , 1.33]
0.94 [0.42 , 2.10]
0.93 [0.39 , 2.20]
0.72 [0.24 , 2.15]
1.46 [0.31 , 6.85]
0.74 [0.24 , 2.30]
0.66 [0.48 , 0.90]Pooled hazard ratio
0.1 0.5
Hazard ratio females/males
1.0 5.0 10.0
RE Model, Heterogeneity: I2=0%
Figure 6 Forest plot of estimated centre-specific hazard ratios
for gender regarding the first appropriate shock together with their
95% CIs and the pooled hazard ratio with a modified Knapp-
Hartung 95% CI. (Note that only centres with at least 10 female pa-
tients and at least 1 observed first appropriate shock both among
males and females were included in this analysis.).
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bias in that physicians tend to withhold ICD-therapy from women
with worse prognosis. An additional factor may be that women in
general have a longer life expectancy than men.
Temporal trends
The DAI-PP registry showed a time-dependent effect of the use of
ICDs. In our study, this could only be observed for appropriate ICD-
shocks. This is explained by changes in programming over the years
allowing for longer detection times and higher rate cut-offs.26,27 In
comparison to the French dataset, we only had data for first inappro-
priate shocks in 1504 patients which may explain that we did not ob-
serve the same time dependent decrease.
Complications
A population-based study from the Ontario ICD database further-
more indicates that women experience more major complications
from their ICD therapy than men (5.4% vs. 3.3%; HR 0.002).28
Interestingly, in this cohort of ICD patients comprising 71% of pa-
tients with primary prevention indication, women had significantly
fewer appropriate shocks (HR 0.69) or antitachycardia pacing (ATP)
than males. In contrast to our observation, the overall mortality did
not differ which is most likely due to the very short follow-up of only
1 year at which point the mortality curves started to separate in our
cohort.
In a recent analysis of more than 38 000, first primary prevention
ICD implants from the Medicare National Cardiovascular Data
Registry (NCDR) only 25% were women, who had higher odds ratios
for procedural complications and 6-months hospital readmission.29 In
contrast to our data, there was no mortality difference which may be
explained by the greater comorbidity and more advanced heart failure
in women in the NCDR and the short follow-up of 6 months.
As reported previously, the mortality and the appropriate shock
rate were lower in patients implanted with a CRT-D,30 but we did
not observe a gender effect as in women mortality and appropriate
shock rates were decreased to the same extent in the CRT-D and
ICD groups.
Risk stratification
Although our data does not justify withholding primary prevention
ICD implantation in women it implies that gender should be taken
into account for future risk stratification models. A clinical risk stratifi-
cation model in a primary prevention ICD population identified male
gender as a strong risk identifier for appropriate shock.4
Limitations
Our study has the limitations of the retrospective design and the re-
sulting in incomplete data capture and heterogeneous data acquisi-
tion across study centres. In this respect, one can note the much
lower number of patients involved in the analysis of the first inappro-
priate shock as compared to the two other end-points considered
(i.e. all-cause mortality and first appropriate shock). Furthermore, the
incomplete data capture on the underlying aetiology and medication
limits the applicability of the results for specific aetiologies and the ef-
fect of drug therapy.
Women significantly less often receive an ICD for primary preven-
tion is one of the main results of our study. Our study is observational
and reflects real life in clinical practice. For statistical comparisons,
however, this imbalance across the gender groups is not ideal. Our
analysis pools together data from 14 centres, which increases the ab-
solute number of women under study and allows for more realistic
estimates of the incidences of events in females (compared to a situ-
ation when only a small number of women is under the observation).
This relatively large sample size helps to overcome limitations in stat-
istical power due to imbalances between gender groups.
The most important strength is that we present unselected real
world data from 14 clinical centres in 11 different European countries
with different reimbursement systems and different local policies
with consistent results in all participating countries.
Conclusions
Our retrospective analysis of 14 local registries in 11 European coun-
tries demonstrates that fewer women than men undergo ICD im-
plantation for primary prevention. Importantly, our follow-up data
indicate that women have a lower risk of death and receive fewer first
appropriate shocks, regardless of where in Europe they were im-
planted. At the same time, they experience the same rate of inappro-
priate ICD shocks. Better risk-stratification is therefore urgently
needed and should comprise gender.
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The Authors would like to apologize for an error in the spelling of one of the author’s names. The correct spelling is Bert Vandenberk.
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